University of North Carolina, Clinical and Translational Research Center (CTRC)
Welcome,         Profile    Billing    Logout  
 8 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Michael
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Active, not recruiting
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Recruiting
3
150
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
11/28
11/28
NCT06522386: GATE1: a Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients with Previously Untreated Mantle Cell Lymphoma

Recruiting
2
40
US
Pirtobrutinib, Rituximab, Rituxan, Venetoclax, ABT-199, GDC-0199
M.D. Anderson Cancer Center
Mantle Cell Lymphoma
02/27
02/29
PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Active, not recruiting
2
3
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B with Inhibitor, Hemophilia B
11/24
02/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Active, not recruiting
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
V-MIND, NCT05910801: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
100
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Lumbar Puncture, LP, Spinal Tap, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
12/29
12/30
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
ONCT-808-101, NCT05588440: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Terminated
1/2
9
US
ONCT-808, Bridging Therapy
Oncternal Therapeutics, Inc
Relapsed/Refractory Aggressive B-Cell Malignancies
09/24
09/24
VISTA, NCT05619471: VIO Imaging for Skin Tissue Assessment

Completed
N/A
65
US
VIO Imaging
Enspectra Health, National Cancer Institute (NCI), National Institutes of Health (NIH)
Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer
08/23
08/23
NCT05940948: [Trial of device that is not approved or cleared by the U.S. FDA]

Withheld
N/A
600
NA
TruScore
[Redacted], Golden State Dermatology
Skin Cancer, Skin Melanoma, Skin Cancers - Squamous Cell Carcinoma, Skin Cancer, Non-Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Lesion
 
 
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
DETECT-POAF, NCT06519747: DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery

Recruiting
N/A
750
Canada
Cardiac monitoring device
Population Health Research Institute
Atrial Fibrillation, Atrial Flutter
08/26
12/26
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting
N/A
120
Europe, Canada, US
Non-Interventional
Regeneron Pharmaceuticals
Hemophilia B
04/26
04/26
Brouwer, Kim LR
No trials found

Download Options